A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs ALT 803 (Primary) ; BCG
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Altor BioScience Corporation
- 22 Jul 2019 Planned number of patients changed from 256 to 596.
- 22 Jul 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2021.
- 22 Jul 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History